Tislelizumab Approved for First-Line in ESCC
The Chinese immune checkpoint inhibitor has picked up its third indication within a year.
Medscape Medical News
source https://www.medscape.com/viewarticle/tislelizumab-receives-first-line-nod-unresectable-metastatic-2025a10005eq?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/tislelizumab-receives-first-line-nod-unresectable-metastatic-2025a10005eq?src=rss
Comments
Post a Comment